期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

罗格列酮心血管风险十余年回顾

下载PDF
导出
摘要 罗格列酮（Rosiglitazone）是噻唑烷二酮类的代表药物之一,为过氧化物酶PPAR-γ受体的高选择性、强效激动剂,可激活PPAR-γ核受体,对参与葡萄糖生成、
作者 赖雁妮 李益明
机构地区 复旦大学附属华山医院内分泌科
出处 《上海医药》 CAS 2010年第12期539-541,共3页 Shanghai Medical & Pharmaceutical Journal
关键词 罗格列酮 心血管风险 PPAR-Γ 噻唑烷二酮类 过氧化物酶 代表药物 高选择性 核受体
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献11

  • 1Kahn SE, Haffner SM, Heise MA, et al. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy [ J ]. N Engl J Med, 2006, 355(23) : 2427-2443.
  • 2朱禧星,潘长玉,李光伟,史虹莉,田慧,杨文英,姜晶,孙晓春,C.DAVIES,王梅,周永浩.磺酰脲类药物合用马来酸罗格列酮治疗2型糖尿病的有效性和安全性观察——随机、双盲、对照、平行、多中心临床试验[J].中华内分泌代谢杂志,2003,19(3). 被引量：36
  • 3文迪雅Ⅳ期临床研究协作组.罗格列酮治疗2型糖尿病的临床观察[J].中华内科杂志,2003,42(9):636-639. 被引量：26
  • 4DREAM ( Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial [ J ]. Lancet, 2006, 368(9541) : 1096-1105.
  • 5Nissen SE, Wolski DK. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes[ J ]. N Engl J Med, 2007, 356(24) : 2457-2471.
  • 6Krall RL. Cardiovascular safety of rosiglitazone [ J]. Lancet, 2007, 369(9578) : 1995.
  • 7Mark A, Hlatky MD, Dena M, et al. Rosiglitazone increased heart failure but did not differ from metformin plus sulphonylurea for other CV outcomes at interim analysis [ J ]. Evid Based Med, 2007, 12(6) :170.
  • 8Lipscombe LL, Gomes T, Levesque LE, et al.Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes [ J ]. JAMA, 2007, 298(22) : 2634- 2643.
  • 9Home PD, Pocock SJ, Nielsen HB, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes(RECORD) : a muhicentre, randomised, open-label trial [J]. Lancet, 2009, 373(9681) : 2125-2135.
  • 10The BARI 2D Study Group. A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease [ J ]. NEJM, 2009, 360(24) : 2503-2515.

二级参考文献19

  • 1Whiteomb RW, Saltiel AR. Thiazolidinediones. Exp Opin Invest Drugs, 1995,4 : 1299-1309.
  • 2lmura H. A novel antidiabetic drug, troglitazone-reason for hope and concern. New Engl J Med, 1998,338:908-909.
  • 3Wolffenbuttel BHR, Gomist R, Squatrito S, et al. Addition of low-dose rosiglitazone to sulfonylurea therapy improves glycaemic control in type 2.diabetic patients. Diabetic Med, 2000,17:40-47.
  • 4Narayan KMV, Gregg EW, Fagot-Campagna A, et al. Diabetes-a common, growing, serious, costly, and potentially preventable public health problem. Diabetes Res Clin Pract, 2000,50 ( Suppl 2 ) : S77-S84.
  • 5Turner RC, Cull CA, Frighi V, Glycemic control with diet, sulfonylurea, mefformin, or insulin in patients with type 2 diabetes mellitus:progressive requirement for multiple therapies ( UKPDS 49), JAMA1999,281:2005-2012.
  • 6Xixing Z, Changyu P, Guangwei L, et al. Rosiglitazone improves glycemic control in Chinese patients with type 2 diabetes mellitus in combination with sulphonylureas. Diabetes, 2001,50 : A542.
  • 7Gomez-Perez FJ, Fanghanel-Salmon G, Barbosa JA, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Met Res Rev, 2002,18 : 127-134.
  • 8Barnett A. Rosiglitazone in type 2 diabetes: an evaluation in British lndo-Asian patients. Diabetic Med, 2001,18 :A40.
  • 9Dogterum P, Jonkman JHG, Vallance SE. Rosiglitazone: no effect on erythrupoiesis or premature red cell destruction. Diabetes, 1999,48 :A98.
  • 10Samraj GP, Kuritzky L, Quillen DM. Improving management of type 2 diabetes mellitus : 5. Thiazolidinediones. Hosp Pract, 2000,35 : 123-124.

共引文献60

上海医药
2010年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部